Common Challenges in Treating Chronic Myeloid Leukemia

Ehab Atallah, MD


October 20, 2022

Treatment with tyrosine kinase inhibitors (TKIs) results in normal life expectancy for most patients with chronic myeloid leukemia, but patients with resistance to frontline treatment, including those with a T315I mutation, present a challenge. In this population, a major molecular response can often be achieved with either ponatinib, a US Food and Drug Administration–approved TKI, or the more recently approved asciminib, which is the first BCR:ABL1 inhibitor to specifically target the ABL myristoyl pocket (STAMP).

Despite good response to therapy, some patients may still report intolerance to side effects necessitating dose reductions. Others who have achieved sustained remission may be candidates for treatment discontinuation, providing certain criteria are met.

In this ReCAP, Dr Ehab Atallah, from the Medical College of Wisconsin, discusses strategies to navigate these situations on the basis of recent evidence.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.